Clinical Trials Logo

Recurrent or Refractory B Cell Malignancy clinical trials

View clinical trials related to Recurrent or Refractory B Cell Malignancy.

Filter by:
  • None
  • Page 1

NCT ID: NCT03207178 Recruiting - Clinical trials for Recurrent or Refractory B Cell Malignancy

Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

Start date: March 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Cluster of differentiation antigen 19(CD19) specifically presents in B lymphocyte cell lines steadily,while not in most normal tissue,including pluripotent hematopoietic stem cells.Cluster of differentiation antigen 20(CD20) presents in 90% of B-cell lymphomas.CD19 antigen is a well-established target for B-cell lymphomas treatment as well as CD20 antigen.Both CD19-targeting CAR T Cells and CD20-targeting CAR T Cells can be used as adoptive cellular immunotherapies for B-cell lymphomas.Though two kinds of single target treatments were proved can induce recession of B-cell lymphomas, the risk of cancer cells to escape and tumor recurrence are still existed. There are no report about combination transfer of two kinds of single target treatments.This research aimed emphasis on safety and therapeutic efficacy evaluation,as well as if combination transfer can decrease recurrence rate.

NCT ID: NCT02794961 Recruiting - Clinical trials for Recurrent or Refractory B Cell Malignancy

CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

Start date: June 2016
Phase: Phase 1/Phase 2
Study type: Interventional

CD19 expression on B cell frequently lost after CD19-targeting CAR-T therapy. In present study, we construct a CD22-targeting chimeric antigen receptor to overcome this issue.